Quick Facts
Plain-English Summary
GHK-Cu (Glycine-Histidine-Lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma albumin by Loren Pickart in 1973 during liver cell aging studies. Unlike many peptide research compounds, GHK-Cu is endogenous — the body produces it, and its plasma concentration measurably declines with age, from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. This age-dependent decline is one of the primary rationales cited for its research interest in anti-aging contexts.
The peptide functions primarily as a copper-delivery system: the tripeptide forms a square-planar complex with a Cu²⁺ ion via the histidine imidazole ring and the N-terminal amine. In this form, GHK-Cu activates a range of wound-healing and regenerative gene networks, including upregulation of collagen types I and III (COL1A1, COL3A1), TGF-β signalling, and superoxide dismutase isoforms (SOD1, SOD3), conferring antioxidant effects. These pathways are well-characterised in vitro and have been reproduced across multiple laboratories — unlike some peptide research programs dominated by a single group.
Two distinct research contexts: GHK-Cu has a meaningful peer-reviewed evidence base as a topical cosmetic ingredient, with published small-scale human studies demonstrating wrinkle reduction and improved skin firmness. Evidence for injectable or subcutaneous use is a separate and much weaker body of literature. Claims extrapolated from topical studies should not be assumed to apply to systemic dosing, and vice versa.
Hair follicle stimulation data is primarily in vitro and rodent. Injectable systemic use for hair regrowth or anti-aging in humans is not supported by controlled trials as of 2026. The compound's long research history — more than 50 years — and its endogenous nature contribute to its high public sentiment score, but should not be conflated with injectable clinical efficacy.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Human fibroblast cultures (in vitro) | GHK-Cu at physiological concentrations (0.1–10 nM) significantly upregulated COL1A1 and COL3A1 gene expression. TGF-β1 stimulation observed across multiple independent cell lines. Reproduced in several laboratories. Pickart L et al. ↗ | Preclinical |
| Rat wound healing model | Topical and subcutaneous GHK-Cu accelerated wound closure and increased collagen density versus vehicle control at 7 and 14 days. Angiogenic effects (VEGF upregulation) observed at wound margins. Finkley MB et al. ↗ | Preclinical |
| Mouse hair follicle model | Topical GHK-Cu significantly enlarged follicle size and extended anagen phase in C57BL/6 mice. Effect dose-dependent. Mechanism proposed as VEGF-mediated dermal papilla proliferation. No comparison to approved hair-loss treatments in this study. | Preclinical |
| SOD1/SOD3 expression (in vitro) | GHK-Cu increased superoxide dismutase mRNA expression in human dermal fibroblasts, consistent with reduced oxidative stress markers. Effect replicated in multiple independent datasets. Supports antioxidant mechanism hypothesis. | Preclinical |
| Anti-inflammatory model (rodent) | Reduced pro-inflammatory cytokine expression (TNF-α, IL-1β) in LPS-stimulated macrophage models. GHK-Cu modulated NF-κB pathway activity. Relevance to injectable anti-inflammatory use in humans unconfirmed. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Topical GHK-Cu cream — wrinkle and firmness study | Topical | — | Limited — Topical Only |
| Topical GHK-Cu — comparative skin quality studies | Topical | — | Limited — Topical Only |
| Injectable / subcutaneous GHK-Cu — all indications | Injectable | — | No Data |
| Hair regrowth — all routes | All | — | No Data |
GHK-Cu has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
GHK-Cu is a permitted cosmetic ingredient in many jurisdictions and has a well-established topical safety profile through decades of formulation use. At concentrations used in skincare (typically 0.1–5%), adverse events are rare and mostly limited to local skin reactions. Its endogenous origin supports a generally favourable safety profile at physiological concentrations.
No formal pharmacokinetic, dosing, or safety studies exist for injectable GHK-Cu in humans. Systemic copper delivery at supraphysiological concentrations carries theoretical risk of copper toxicity. The peptide's effects on gene networks governing collagen synthesis and cell proliferation have not been assessed for unintended systemic consequences at injectable doses.
- Injection site redness, swelling, and mild bruising
- Transient skin flushing or warmth (possibly copper vasodilation)
- Metallic taste reported by some users
- No pharmacovigilance database exists for injectable GHK-Cu
- Quality and purity of injectable preparations vary widely — no approved standard
- Known copper metabolism disorders (Wilson's disease, Menkes disease)
- Active or suspected malignancy (pro-angiogenic effects)
- Pregnancy or breastfeeding
- Concurrent use of copper-chelating medications
- Children and adolescents
GHK-Cu is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of GHK-Cu for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
The endogenous angle here actually matters more than people give it credit for. This isn't a synthetic molecule — the body already makes it, knows how to bind it, and there's a measurable age-related decline. That's a very different risk profile from most synthetic peptides. The mechanistic case for collagen upregulation via COL1A1/COL3A1 is genuinely solid in vitro — replicated across multiple groups, not just one lab. The gap is purely translational: nobody has run an injectable PK study in humans. That's the missing piece.
The endogenous argument cuts both ways though. Plasma concentration declines with age, yes — but that doesn't automatically mean supplementing it restores youthful function. That's the classic hormone replacement logic that took 30 years of clinical trials to properly evaluate. GHK-Cu needs the same rigour before anyone should be injecting it systemically.
What frustrates me about the GHK-Cu community is the conflation of topical evidence with injectable justification. Gorouhi and Maibach's review is legitimately interesting — small studies, industry-funded caveats acknowledged, but actual human skin improvement data exists. That evidence applies to a cream sitting on the skin for hours. It says nothing about what happens when you inject it subcutaneously and it hits the bloodstream. They are completely different pharmacological questions and the community treats them as interchangeable.
The hair regrowth claims are the weakest part of the GHK-Cu evidence stack. The mouse follicle data is interesting — anagen phase extension and dermal papilla proliferation are plausible mechanisms — but the leap from C57BL/6 mice to injectable human hair regrowth is enormous. Nobody is comparing this to minoxidil or finasteride in a controlled setting. The "regrows hair fully" claims circulating in vendor content are miles ahead of the evidence and should be treated accordingly.
Agreed. This is where the 50-year research history actually works against the compound in some ways — Pickart's own claims became progressively broader over time, and the community absorbed that framing without the methodological rigor that should have accompanied it. The in vitro collagen data is real. Everything beyond that needs its own evidence.
From a clinical perspective, the topical evidence — while imperfect — is among the stronger cosmetic peptide datasets. Small studies, yes, but the skin firmness and wrinkle data in the Gorouhi review is more rigorous than most cosmetic ingredient claims you'll encounter. If I'm ranking it honestly: topical GHK-Cu for skin aging is credible at a moderate evidence level; injectable for any systemic use is research only with no human safety or efficacy data. That distinction is critical and frequently ignored in the community. The compound deserves the topical evidence it has — it does not deserve the injectable hype it's accumulated.